INCA24,
INCB-018424,
INCB018424,
ruxolitinib,
Ruxolitinib,
941678-49-5,
Ruxolitinib (INCB018424),
INCB018424,
INCB-018424,
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile,
INCB 018424,
UNII-82S8X8XX8H,
INCB18424,
82S8X8XX8H,
INCB018424 (Ruxolitinib),
CHEBI:66919,
(R)-ruxolitinib,
C17H18N6,
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile,
R-Ruxolitinib,
INC424,
Ruxolitinib [USAN:INN],
INCB 18424,
(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile,
(3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}pyrazol-1-yl)propanenitrile,
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile,
INC 424,
Ruxolitinib (USAN/INN),
INCB18424,Ruxolitinib,
INCB424,
SCHEMBL171319,
BIFK0027,
GTPL5688,
INCB018424 - Ruxolitinib,
CHEMBL1789941,
SCHEMBL16546708,
HSDB 8259,
DTXSID10240930,
SYN1120,
HFNKQEVNSGCOJV-OAHLLOKOSA-N,
ZX-AFC000454,
Ruxolitinib, 941678-49-5,
ACT06813,
AOB87783,
EX-A1670,
KS-000006SM,
ABP000827,
ABP000833,
BDBM50355501,
MFCD12031592,
s1378,
ZINC43207851,
ACN-031567,
BCP9000784,
CS-0864,
DB08877,
INCB018424(Ruxolitinib)/Ruxolitinib,
PB28380,
NCGC00244253-01,
NCGC00244253-02,
NCGC00244253-11,
AC-24280,
AK-48608,
AS-18619,
BR-48608,
HY-50856,
QC-11806,
AJ-108289,
AX8165439,
ST2407566,
FT-0674485,
W9658,
INCB018424 /INCB-018424,
A14955,
D09959,
Q-4578,
AB01565782_02,
BRD-K53972329-001-02-1,
BRD-K53972329-001-03-9,
(3R)-3-cyclopentyl-3-[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile,
(betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile,
(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H -pyrazol-1-yl)-3-cyclopentylpropanenitrile,
3-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(beta-R)-1H-pyrazole-1-propanenitrile,
A-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(AR)-1H-pyrazole-1-propanenitrile,
1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-,
Jakafi,
Jakavi,
Ruxolitinib phosphate,
Ruxolitinib [INN],
D04LKS,
INCA24,
Ruxolitinib (JAK inhibitor),
cc-189,
INCB018424(Ruxolitinib),
CS-T-61211,
Ruxolitinib, 98% - 100MG 100mg,
A3012,
A3781,
A11041,
C540383,
1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-,
?-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(?R)-1H-pyrazole-1-propanenitrile,
1092939-17-7,
(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2, 3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile,
|A-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(|AR)-1H-pyrazole-1-propanenitrile,
1160597-27-2,
941685-37-6,